Back to Discover

INBX · Biotech · Nasdaq · As of 21 Nov 2026

Inhibrx Biosciences, Inc. stock: filings, catalysts and timeline

Sign in to follow

AIR Score

0100
46

Cautious · 46 / 100

AIR confidence

Support behind the full AIR read.

What is this? →

How much data stands behind the whole AIR read — all five perspectives, not just the Discovery Gap. Each perspective reports how complete its inputs are, and these are combined in the same proportions as the AIR Score; a perspective AIR could not score adds nothing, so missing data lowers this figure. It describes the data, not the company.

The Discovery Gap

LOWHIGHVERY HIGH

High

Gap confidence

How fully AIR could measure this Gap — separate from the AIR Score's confidence.

What is this? →

How fully AIR could measure both sides of the Discovery Gap: the documented progress (News flow) and market attention (Recognition). It takes the weaker of the two, and reads zero when either side has no measurement. It describes the data, not the company.

Five perspectives

  • FundamentalsWhat is this?Not scored — outside AIR's $300M–$20B fundamentals band

    How the business is doing on its own reported US-GAAP numbers — growth, margins, cash generation, balance-sheet strength, capital efficiency and dilution — compared with sector peers.

    Source: SEC XBRL financial statements.

  • ValueWhat is this?Too few of the required measures on file

    How the shares are priced against sector peers, against the company's own recent history, and against a simple cash-flow estimate, using the filing numbers and the current price. AIR shows this as a band, never as a target price.

    Source: SEC XBRL financial statements and end-of-day prices.

  • News flowWhat is this?Balanced

    What the company has documented recently: material 8-K events (contracts, deals, results, leadership changes) and FDA approvals, weighted by recency and type. A language model's reading of each 8-K helps classify whether it is positive or negative. Filings, not press or social media.

    Source: SEC EDGAR 8-K filings and FDA approvals.

  • MomentumWhat is this?Watch

    The longer-term market read: the trend in end-of-day prices, strength against the market and the sector, and trading volume over roughly the past three to twelve months. It is shown, never used to rank the Shortlist.

    Source: End-of-day prices.

  • SafetyWhat is this?Balanced

    The risk side: leverage, liquidity, cash runway, dilution, revenue and margin swings, company size and pre-commercial status, negative 8-K events (including legal and regulatory ones), and share-price drawdown and volatility. Higher means fewer of those risk markers.

    Source: SEC XBRL financial statements, SEC EDGAR 8-K filings and end-of-day prices.

Rating words, not raw numbers.

How AIR scores →

Discovery Gap: High (38/100) · Gap confidence 53/100

Discovery gap

Filings show more traction than the tape reflects.

Low is the most common level — the cut-offs are fixed, and levels can shift as scores refresh.

What is this?

How far documented progress (News flow) runs ahead of market attention. Attention is measured from institutional holdings reported to the SEC, trading volume, price behaviour and how richly the shares are valued — not from social media or analyst ratings.

Source: SEC EDGAR filings (8-K and 13F), FDA approvals and end-of-day prices.

How levels work. The levels use fixed cut-offs, but market attention is ranked against the other ~1,800 companies AIR covers that day (valuation against the same sector). Documented progress counts filings from the past 18 months, newer ones weighing more; attention uses the latest quarter of institutional holdings, the last three to six months of trading, and six to twelve months of price behaviour. Many companies show a Low Gap or none at all — a gap needs filings that read more positively than neutral. A level can change from one day to the next as scores refresh and the other companies move.

This month at a glance

AIR Score™ change: -2Slipped -2 on softer inputs.
Window31 Oct 2026 → 21 Nov 2026
Momentum-2Weighed on the score this month.

Evidence timeline

What changed — last 90 days

As of 14 Nov 2026
  1. The company reported Q3 2026 net loss of $38.7M versus $35.3M in the prior year, debt of $275M, stockholders' equity of $85.9M, $2M Pfizer license revenue, and advancing clinical milestones.

    Results · 8-K filed 13 Nov →

  2. The company filed its quarterly report for the period ending 30 September 2026.

    Quarterly/annual report · 10-Q filed 13 Nov →

What the company disclosed, not verified by AIR · sources link to the Evidence timeline below.

  1. Expected
  2. Fri 19 Mar · expected 10-K

    Last year filed 19 Mar 2026.

  3. Fri 14 May · expected 10-Q

    Last year filed 14 May 2026.

  4. Filed
  5. Tue 17 Nov · 8-K

    8-K · Item 8.01 — Other events

    Gap High · 27 → High · 38

    Progress is running ahead of attention.

    The price trend weakened.

  6. Fri 13 Nov · 10-Q

    Quarterly report (10-Q), period ending 30 Sep 2026

    Gap High · 39 → High · 27

    The gap narrowed as the filings read less positively.

    The price trend weakened.

  7. Fri 13 Nov · 8-K

    8-K · Item 2.02 — Results of operations

    Q3 2026 results show $38.7M net loss (vs. $35.3M prior year), increased debt to $275M, and negative stockholders' equity of $85.9M. Offset by $2M Pfizer license revenue, R&D cost reduction, and advancing clinical milestones for two programs.

    Gap High · 39 → High · 27

    The gap narrowed as the filings read less positively.

    The price trend weakened.

  8. Mon 28 Sep · 8-K

    Current report (8-K)

  9. Tue 8 Sep · 8-K

    8-K · Item 8.01 — Other events

  10. Thu 13 Aug · 10-Q

    Quarterly report (10-Q), period ending 30 Jun 2026

  11. Thu 13 Aug · 8-K

    8-K · Item 2.02 — Results of operations

  12. Thu 16 Jul · 8-K

    8-K · Items 1.01, 2.03, 3.02 — Material agreement

  13. Mon 15 Jun · 8-K

    8-K · Item 8.01 — Other events

  14. Wed 3 Jun · 8-K

    Current report (8-K)

  15. Thu 14 May · 10-Q

    Quarterly report (10-Q), period ending 31 Mar 2026

  16. Thu 14 May · 8-K

    8-K · Item 2.02 — Results of operations

  17. Mon 11 May · 8-K

    8-K · Item 8.01 — Other events

  18. Tue 21 Apr · 8-K

    8-K · Item 8.01 — Other events

  19. Thu 19 Mar · 8-K

    8-K · Item 2.02 — Results of operations

  20. Thu 19 Mar · 10-K

    Annual report (10-K), FY2025

  21. Mon 23 Feb · 8-K

    Current report (8-K)

  22. Tue 16 Dec · 8-K

    8-K · Item 8.01 — Other events

  23. Fri 14 Nov · 8-K

    8-K · Item 2.02 — Results of operations

  24. Fri 14 Nov · 10-Q

    Quarterly report (10-Q), period ending 30 Sep 2025

  25. Thu 23 Oct · 8-K

    8-K · Item 8.01 — Other events

Solid dots: a filing AIR classified as material. Grey: routine. Hollow: expected, from last year's dates — not a forecast.

Ask AIR

What would change our view

A weaker balance sheet in the next filing cycle, a material regulatory setback, or attention arriving — which closes the gap by design would move the score, and the page would show which one did.

Research, not tips. No buy/sell recommendations, no price forecasts. Every score is derived from public filings and market data — figures round to whole numbers and refresh each trading day.